Brokerages expect that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will announce earnings of ($0.37) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with estimates ranging from ($0.38) to ($0.36). Xenon Pharmaceuticals posted earnings of ($0.45) per share during the same quarter last year, which indicates a positive year over year growth rate of 17.8%. The firm is expected to issue its next quarterly earnings results on Wednesday, March 6th.

On average, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.44). For the next year, analysts forecast that the firm will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.01) to ($1.52). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.16).

Several equities research analysts have recently commented on XENE shares. BidaskClub upgraded shares of Xenon Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 5th. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 11th. Jefferies Financial Group restated a “buy” rating and set a $16.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 10th. Finally, Stifel Nicolaus boosted their target price on shares of Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $14.33.

Shares of XENE opened at $7.80 on Thursday. The company has a market capitalization of $212.77 million, a price-to-earnings ratio of -4.53 and a beta of 1.14. Xenon Pharmaceuticals has a twelve month low of $2.35 and a twelve month high of $15.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 29.36 and a quick ratio of 29.36.

Several institutional investors have recently modified their holdings of XENE. JPMorgan Chase & Co. acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter worth $111,000. Trexquant Investment LP acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter worth $148,000. Bank of Montreal Can lifted its stake in shares of Xenon Pharmaceuticals by 433.3% in the 3rd quarter. Bank of Montreal Can now owns 11,721 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 9,523 shares during the period. OppenheimerFunds Inc. increased its holdings in shares of Xenon Pharmaceuticals by 104.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 22,481 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 11,476 shares in the last quarter. Finally, Spark Investment Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 105.5% in the 2nd quarter. Spark Investment Management LLC now owns 26,100 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 13,400 shares in the last quarter. Institutional investors and hedge funds own 69.71% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

Further Reading: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.